1. Introduction {#sec1-molecules-23-01929}
===============

Cyclooxygenase (COX) is an enzyme involved in the biosynthesis of prostaglandins, prostanoids, and thromboxins from arachidonic acid and drugs that block COX-1 and COX-2 isoenzymes that are non-steroidal anti-inflammatory drugs (NSAIDs) \[[@B1-molecules-23-01929],[@B2-molecules-23-01929],[@B3-molecules-23-01929]\]. Of these two isoenzymes of COX, COX-1, is constitutively expressed in many tissues and is responsible for the production of prostanoids associated with normal haemostatic functions \[[@B4-molecules-23-01929]\]. In contrast, COX-2 is an inducible enzyme involved in cellular responses associated with inflammation \[[@B1-molecules-23-01929],[@B2-molecules-23-01929],[@B3-molecules-23-01929],[@B4-molecules-23-01929]\]. Another variant enzyme of the COX family, COX-3, has been recently identified and is believed to mediate fever; its inhibition is involved in the antipyretic effect of NSAIDs \[[@B5-molecules-23-01929]\]. Expression of COX-2 proteins and mRNA in human subjects show that COX-2 levels in normal tissues are the highest in the kidney followed by brain, then the spleen, liver, heart, and intestine \[[@B6-molecules-23-01929],[@B7-molecules-23-01929],[@B8-molecules-23-01929]\]. COX-2 expression is upregulated in the inflammatory process in conditions, such as cancers, arthritis, autoimmune disorders, ischemic heart disease, stroke, organ rejection, and neurodegenerative diseases, like Alzheimer's and Parkinson's diseases \[[@B9-molecules-23-01929],[@B10-molecules-23-01929],[@B11-molecules-23-01929],[@B12-molecules-23-01929],[@B13-molecules-23-01929]\]. Due to the involvement of COX-2 in diseases or disease processes, quantifying COX-2 expression is a potential biological marker for early diagnosis and for monitoring disease progression. Measurement of target occupancy allows drug development of new COX-2 NSAIDs, and an indicator of effective treatment. Since, COX-2 is constitutively expressed in many organs, and COX-2 inhibitors are known to inhibit platelets in the blood, side effects associated with COX-2 inhibitors as therapeutics are of major concern. The low injected mass of a radioligand that is required for quantitative PET imaging means that highly selective COX-2 NSAID drugs are potential candidates to be radiolabeled with PET isotopes for use as imaging agents. We chose celecoxib, a highly selective COX-2 inhibitor (COX-2 and COX-1 IC~50~ values of celecoxib are 40 and 17,000 nM, respectively), and is safe to use in humans since it is an FDA-approved prescription drug, as a candidate for PET ligand development \[[@B14-molecules-23-01929],[@B15-molecules-23-01929],[@B16-molecules-23-01929]\]. We previously radiolabeled celecoxib with \[^18^F\]isotope and found that the tracer undergoes rapid \[^18^F\]defluorination in rodents \[[@B17-molecules-23-01929]\]. However, biodistribution and pharmacokinetics studies with unlabeled or \[^14^C\]-labeled celecoxib showed that the ligand did not undergo defluorination in rat and human subjects \[[@B18-molecules-23-01929],[@B19-molecules-23-01929]\]. Therefore, the de\[^18^F\]fluorination of \[^18^F\]celecoxib is not likely due to the enzymatic process, but possibly related to its auto radiolysis in vivo. Although de\[^18^F\]fluorination was relatively slower in nonhuman primates compared with rodents \[[@B17-molecules-23-01929]\], we decided to pursue \[^11^C\]celecoxib synthesis and employed a Stille coupling reaction to develop a one pot synthesis \[[@B20-molecules-23-01929]\]. Herein, we describe the brain uptake, whole body biodistribution, and dosimetry of \[^11^C\]celecoxib in non-human primates ([Figure 1](#molecules-23-01929-f001){ref-type="fig"}).

2. Results and Discussion {#sec2-molecules-23-01929}
=========================

2.1. Radiochemistry of \[^11^C\]Celecoxib and Cross Selectivity of Celecoxib to Brain Targets {#sec2dot1-molecules-23-01929}
---------------------------------------------------------------------------------------------

\[^11^C\]Celecoxib was synthesized via a one pot procedure developed based on our previously published method in 40 min at the end of bombardment (EOB) and in 8 ± 2% yield at EOB with \>95% radiochemical purity along with a molar activity of 39 ± 6.6 GBq/micromol (n = 12). Celecoxib did not show significant affinity to a variety of competitive brain receptors, transporters, biogenic amines, and proteins (Ki \> 10 microM) ([Table 1](#molecules-23-01929-t001){ref-type="table"}) based on the National Institute of Mental Health--Psychoactive Drug Screening Program (NIMH-PDSP) binding assays \[[@B21-molecules-23-01929],[@B22-molecules-23-01929]\].

2.2. PET Imaging of \[^11^C\]Celecoxib in Baboon Brain {#sec2dot2-molecules-23-01929}
------------------------------------------------------

PET imaging in an anesthetized baboon, corresponding to an injected mass ≤1.5 micrograms shows that \[^11^C\]celecoxib penetrates the blood brain barrier (BBB) and the radioactivity is retained in the brain ([Figure 2](#molecules-23-01929-f002){ref-type="fig"}). Decay corrected time activity curves (TACs) expressed in the standard uptake value (SUV) indicated a peak uptake of the radiotracer at an interval between three to 10 min post injection in various brain regions, followed by a gradual washout of activity. \[^11^C\]celecoxib exhibited a somewhat heterogeneous distribution in the baboon brain ([Figure 2](#molecules-23-01929-f002){ref-type="fig"} and [Figure 3](#molecules-23-01929-f003){ref-type="fig"}). The radioactivity levels in baboon plasma peaked around one min post injection, followed by a gradual clearance ([Figure 4](#molecules-23-01929-f004){ref-type="fig"}A). HPLC analyses of the plasma samples indicated a fast metabolism of \[^11^C\]celecoxib, with 17% unmetabolized radioligand at 90 min ([Figure 4](#molecules-23-01929-f004){ref-type="fig"}B). Two-tissue compartment (2-TC), Logan plot, and likelihood estimation in graphical analysis (LEGA) yielded comparable estimates of \[^11^C\]celecoxib total volume of distribution (V~T~) across most regions ([Figure 5](#molecules-23-01929-f005){ref-type="fig"}) \[[@B23-molecules-23-01929],[@B24-molecules-23-01929],[@B25-molecules-23-01929]\]. On average, the highest V~T~ was found in the midbrain, followed by the cortical regions ([Figure 5](#molecules-23-01929-f005){ref-type="fig"}).

2.3. Whole Body Biodistribution and Radiation Dosimetry Estimation of \[^11^C\]Celecoxib in Baboons {#sec2dot3-molecules-23-01929}
---------------------------------------------------------------------------------------------------

All animals tolerated the intravenous injection of \[^11^C\]celecoxib. There was no significant physiological effect, such as diastolic blood pressure, heart rate, respiratory rate, or rectal temperature, with the administration of \[^11^C\]celecoxib in baboons. [Figure 6](#molecules-23-01929-f006){ref-type="fig"} shows the representative whole body distribution of \[^11^C\]celecoxib. Radioligand exhibited binding to the brain, heart, and kidney, the organs known for the constitutive expression of COX-2. The liver, gallbladder, and urinary bladder showed the highest retention of radioactivity. Decay-corrected and non-decay-corrected time activity curves for various organs are reported in [Figure 7](#molecules-23-01929-f007){ref-type="fig"}. The area under the curve was obtained from the sum of trapezoidal integration and the integral of the exponential functions from time zero to infinity. The liver shows the highest residence time ([Table 2](#molecules-23-01929-t002){ref-type="table"}). Residence times were used as an input function for dosimetry estimations with the Organ Level Internal Dose Assessment (OLINDA) program.

[Table 3](#molecules-23-01929-t003){ref-type="table"} and [Table 4](#molecules-23-01929-t004){ref-type="table"} show the dosimetry estimates extrapolated for adult male (70 kg) and adult female (57 kg) human subjects, respectively. This data indicate elimination of \[^11^C\]celecoxib via the hepatobiliary and renal systems. The gallbladder received the highest estimated radiation dose for males and females and it was the critical organ (1.48E-02 rad/mCi and 1.65E-02 rad/mCi), respectively.

3. Experimental {#sec3-molecules-23-01929}
===============

3.1. Brain PET Imaging and Quantification of \[^11^C\]Celecoxib in Baboons {#sec3dot1-molecules-23-01929}
--------------------------------------------------------------------------

All animal experiments were carried out with the approval of the Institutional Animal Care and Use Committees (IACUC) of Columbia University Medical Center and the New York State Psychiatric Institute (IACUC approval no.\# AC-AAAA0869). Brain PET scanning was performed in an anesthetized male baboon with an ECAT EXACT HR+ scanner (CPS/Knoxville, TN, USA) as described previously \[[@B26-molecules-23-01929]\]. An arterial line was placed to collect blood samples for determination of the arterial input function. The head was positioned at the center of the field of view, and a 10 min transmission scan was performed before the tracer injection. \[^11^C\]celecoxib was injected (114.7 MBq) as intravenous bolus over 30 s, and emission data were collected for 120 min in 3-dimensional mode. Plasma samples were collected using an automated system every 10 s for the first 2 min, and manually thereafter for a total of 34 samples (0.75 mL) up to 120 min post injection. All PET images were co-registered with magnetic resonance images (MRI) using FMRIB's Linear Image Registration Tool (FLIRT). Regions of interest (ROIs) drawn on the animal's MRI scan were transferred to co-registered automated image registration (AIR) frames of PET data. Total plasma counts and high-performance liquid chromatography (HPLC) assay of six of the collected arterial blood samples (\~2 mL) provided amounts of total radiotracer counts and the unmetabolized parent compound in plasma \[[@B26-molecules-23-01929]\]. The metabolite-corrected arterial input function was then obtained by multiplying the parent fraction curve (fitted using a Hill function \[[@B27-molecules-23-01929]\]) by the individual total plasma counts, and by fitting the resulting data points with a combination of a straight line (before the peak) and the sum of three decreasing exponentials (after the peak). Regional total distribution volumes (V~T~, ml of plasma/cm^3^ of tissue) of \[^11^C\]celecoxib were estimated using the 2-TC and graphical analyses with Logan and LEGA and the metabolite-corrected arterial input function \[[@B23-molecules-23-01929],[@B24-molecules-23-01929],[@B25-molecules-23-01929]\].

3.2. Whole Body Biodistribution and Radiation Dosimetry Estimations of \[^11^C\]Celecoxib in Baboons {#sec3dot2-molecules-23-01929}
----------------------------------------------------------------------------------------------------

Whole body biodistribution and dosimetry estimations of \[^11^C\]celecoxib in baboons were performed based on a protocol we developed earlier \[[@B28-molecules-23-01929],[@B29-molecules-23-01929],[@B30-molecules-23-01929],[@B31-molecules-23-01929],[@B32-molecules-23-01929]\]. In brief, whole body PET scans were performed in 2 adult male baboons on 6 occasions with an ECAT ACCEL (Siemens Medical Solutions, Inc., Knoxville, TN, USA) with an intravenous injection of 111 ± 18.5 MBq \[^11^C\]celecoxib in two-dimensional mode for 120 min in 5 bed positions. Image analyses were performed with software Medx 3.3 (Sensor Systems, Sterling, VA, USA). Organs that were clearly visible on all scans were identified for ROIs and dosimetry analyses. The area under the curve was obtained by trapezoidal integration of the radioligand time activity curves. The organ residence times were calculated from the ratio of area under the TACs to infinity over the initial total body activity. The Organ Level Internal Dose Assessment (OLINDA) software (Hermes Medical Solutions Inc., Greenville, NC, USA) was used to calculate the absorbed radiation dose \[[@B33-molecules-23-01929]\]. The residence times were calculated based on the adult male (70 kg) and adult female (57 kg) human phantoms in OLINDA. The activity not included in the organ ROIs, or the remainder blood activity, was not measured. In the residence time calculation, an organ called the remainder of the body was obtained from the sum of all organ activity subtracted from the total dose.

Images were transferred into the image analysis software Medx 3.3 (Sensor Systems, Sterling, VA, USA). ROIs were drawn around organs that were identified clearly on all scans. The area under the curve was obtained by trapezoidal integration of the radioligand time activity curves (TACs) data points. The organ residence times were then calculated from the ratio of area under the TACs to infinity over the initial total body activity. The absorbed radiation dose was calculated using the Organ Level Internal Dose Assessment (OLINDA) software \[[@B33-molecules-23-01929]\]. The residence times were extrapolated to the adult male (70 kg) and adult female (57 kg) human phantoms in OLINDA. The remainder of the blood activity (activity not included in the organ ROIs) was not measured. In the dosimetry calculation, an "organ" called the rest of the body was used and its TAC was obtained from the sum of all organ activity subtracted from the total dose and entered into the OLINDA program as the "remainder of the body".

4. Conclusions {#sec4-molecules-23-01929}
==============

All animals tolerated intravenous doses of \[^11^C\]celecoxib in baboons, with no meaningful physiological or pharmacological effects. \[^11^C\]celecoxib penetrated the BBB and exhibited a somewhat heterogeneous binding in the baboon brain with washout kinetics amenable for tracer kinetic modeling. Biodistribution and dosimetry estimation in baboons suggest that the single study dose limit of \[^11^C\]celecoxib, extrapolated to male and female human subjects, is 30 mCi, which is below the dose limit for research subjects based on the 21 CFR 361.1. This dose limit allows two or three PET sessions up to 10 mCi single doses of \[^11^C\]celecoxib in a human subject per year. The gallbladder exhibits the critical organ for \[^11^C\]celecoxib for male and female subjects. Therefore, existing human safety data and the dosimetry findings make \[^11^C\]celecoxib suitable for human use for proof of concept studies.
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![Chemical structure of \[^11^C\]celecoxib.](molecules-23-01929-g001){#molecules-23-01929-f001}

![MRI and co-registered positron emission tomography (PET) images (sum of radioactivity between 0 and 120 min after injection) of \[^11^C\]celecoxib. PET scan in baboon brain.](molecules-23-01929-g002){#molecules-23-01929-f002}

![Decay-corrected time activity curves of \[^11^C\]celecoxib in the baboon brain normalized by injected radioactive dose and body weight.](molecules-23-01929-g003){#molecules-23-01929-f003}

![(**A**) Decay-corrected plasma activity of \[^11^C\]celecoxib in the baboon. (**B**) Unmetabolized parent fraction of \[^11^C\]celecoxib in baboon plasma.](molecules-23-01929-g004){#molecules-23-01929-f004}

![Metabolite-corrected total volume of distribution of \[^11^C\]celecoxib in the baboon brain.](molecules-23-01929-g005){#molecules-23-01929-f005}

![A representative biodistribution and sum of slices over 110 min whole body image of \[^11^C\]celecoxib in the baboon (Left: Transaxial; middle: Coronal; right: Sagittal).](molecules-23-01929-g006){#molecules-23-01929-f006}

![Time activity curves (TACs) of \[^11^C\]celecoxib in different organs of the baboon. Data are the averages determined from two adult male baboons in six occasions (The blue curves (dotted lines) are decay-corrected and the red curves (solid lines) are non-decay-corrected TACs for each organ) (**A**: Liver; **B**: Urinary bladder; **C**: Gallbladder; **D**: Kidney, **E**: Head; **F**: Intestine; **G**: Heart; **H**: Lung).](molecules-23-01929-g007){#molecules-23-01929-f007}

molecules-23-01929-t001_Table 1

###### 

Affinity and selectivity of celecoxib.

  Targets                              Affinity (nM)   Targets                      Affinity (nM)
  ------------------------------------ --------------- ---------------------------- ---------------
  COX-2^14^                            40 nM           COX-1^14^                    17,000
  5-hydroxytryptamin 1-7 receptors     \>10,000        Adenosine receptors          \>10,000
  Alpha1,2 receptors                   \>10,000        AMPA receptors               \>10,000
  Beta1-3 receptors                    \>10,000        Calcium channel receptor     \>10,000
  Benzodiazepine receptors             \>10,000        Dopamine 1-5 receptors       \>10,000
  Cannabinoid 1,2 receptors            \>10,000        Dopamine transporter         2487
  Delta opioid receptor                \>10,000        Prostanoid receptors         \>10,000
  Prostaglandin receptors              \>10,000        Histamine 1-4 receptors      \>10,000
  Gamma-aminobutyric acid receptors    \>10,000        Kainate receptors            \>10,000
  Imidazoline receptor                 \>10,000        Kappa Opioid receptor        \>10,000
  Human Ether-à-go-go                  \>10,000        Muscarinic 1-5 receptors     \>10,000
  Norepinephrine transporter           \>10,000        mGluR receptors              \>10,000
  Neurokinin receptors                 \>10,000        Mu opioid receptor           \>10,000
  Neurotensin receptors                \>10,000        Serotonin transporter        \>10,000
  Sodium Channel                       \>10,000        Smoothened receptor          \>10,000
  Nociceptin opioid peptide receptor   \>10,000        Sigma 1, 2 receptors         \>10,000
  NMDA receptors                       \>10,000        VMAT receptors               \>10,000
  Vanilloid receptor                   \>10,000        NR2B receptor                \>10,000
  Oxytocin receptors                   \>10,000        Protein kinase C receptors   \>10,000
  Peripheral benzodiazepine receptor   \>10,000        Vasopressin receptors        \>10,000

molecules-23-01929-t002_Table 2

###### 

Average residence time of \[^11^C\]celecoxib (unit: Bq·h/Bq).

  Organ             Residence Time
  ----------------- ----------------
  Gall Bladder      0.015627
  Urinary Bladder   0.01683
  Brain             0.006497
  Heart             0.00464
  Small Intestine   0.010684
  Kidneys           0.015125
  Liver             0.063269
  Lungs             0.002582
  Spleen            0.001115
  Stomach wall      0.003536
  Vertebra          0.000769
  Remainder         0.349441

molecules-23-01929-t003_Table 3

###### 

Dosimetry estimation of \[^11^C\]celecoxib extrapolated to adult males.

  Organ                       mGy/MBq         Mrad/mCi           Mrad/ID            \% Limit
  --------------------------- --------------- ------------------ ------------------ ----------
  Adrenals                    3.45 × 10^−3^   1.28 × 10^1^       3.83 × 10^2^       7.7
  Brain                       1.82 × 10^−3^   6.73               2.02 × 10^2^       4.0
  Breasts                     2.04 × 10^−3^   7.55               2.26 × 10^2^       4.5
  **Gallbladder Wall**        3.99 × 10^−2^   **1.48** × 10^2^   **4.43** × 10^3^   **88.6**
  LLI Wall                    2.95 × 10^−3^   1.09 × 10^1^       3.27 × 10^2^       6.5
  Small Intestine             6.17 × 10^−3^   2.28 × 10^1^       6.85 × 10^2^       13.7
  Stomach Wall                4.66 × 10^−3^   1.72 × 10^1^       5.17 × 10^2^       10.3
  ULI Wall                    3.55 × 10^−3^   1.31 × 10^1^       3.94 × 10^2^       7.9
  Heart Wall                  5.34 × 10^−3^   1.98 × 10^1^       5.93 × 10^2^       11.9
  Kidneys                     1.51 × 10^−2^   5.59 × 10^1^       1.68 × 10^3^       33.5
  Liver                       1.18 × 10^−2^   4.37 × 10^1^       1.31 × 10^3^       26.2
  Lungs                       1.97 × 10^−3^   7.29               2.19 × 10^2^       4.4
  Muscle                      2.43 × 10^−3^   8.99               2.70 × 10^2^       5.4
  Ovaries                                                                           
  Pancreas                    3.65 × 10^−3^   1.35 × 10^1^       4.05 × 10^2^       8.1
  Red marrow                  2.23 × 10^−3^   8.25               2.48 × 10^2^       8.3
  Osteogenic Cells            3.28 × 10^−3^   1.21 × 10^1^       3.64 × 10^2^       7.3
  Skin                        1.90 × 10^−3^   7.03               2.11 × 10^2^       4.2
  Spleen                      3.16 × 10^−3^   1.17 × 10^1^       3.51 × 10^2^       7.0
  Testes                      2.34 × 10^−3^   8.66               2.60 × 10^2^       8.7
  Thymus                      2.40 × 10^−3^   8.88               2.66 × 10^2^       5.3
  Thyroid                     2.25 × 10^−3^   8.33               2.50 × 10^2^       5.0
  Urinary Bladder Wall        1.38 × 10^−2^   5.11 × 10^1^       1.53 × 10^3^       30.6
  Uterus                                                                            
  Total Body                  2.81 × 10^−3^   1.04 × 10^1^       3.12 × 10^2^       
                              **mSv/MBq**     **mrem/mCi**       **mrem/ID**        
  Effective dose equivalent   6.97 × 10^−3^   2.58 × 10^1^       7.74 × 10^2^       
  Effective dose              4.04 × 10^−3^   1.49 × 10^1^       4.48 × 10^2^       14.9

molecules-23-01929-t004_Table 4

###### 

Dosimetry estimation of \[^11^C\]celecoxib extrapolated to adult females.

  Organ                       mGy/MBq         Mrad/mCi           Mrad/ID            \% Limit
  --------------------------- --------------- ------------------ ------------------ ----------
  Adrenals                    4.37 × 10^−3^   1.62 × 10^1^       4.85 × 10^2^       9.7
  Brain                       2.18 × 10^−3^   8.07               2.42 × 10^2^       4.8
  Breast                      2.60 × 10^−3^   9.62               2.89 × 10^2^       5.8
  **Gallbladder Wall**        4.47 × 10^−2^   **1.65** × 10^2^   **4.96** × 10^3^   **99.2**
  LLI Wall                    3.73 × 10^−3^   1.38 × 10^1^       4.14 × 10^2^       8.3
  Small Intestine             7.22 × 10^−3^   2.67 × 10^1^       8.01 × 10^2^       16.0
  Stomach Wall                5.65 × 10^−3^   2.09 × 10^1^       6.27 × 10^2^       12.5
  ULI Wall                    4.43 × 10^−3^   1.64 × 10^1^       4.92 × 10^2^       9.8
  Heart Wall                  6.94 × 10^−3^   2.57 × 10^1^       7.70 × 10^2^       15.4
  Kidneys                     1.66 × 10^−2^   6.14 × 10^1^       1.84 × 10^3^       36.9
  Liver                       1.56 × 10^−2^   5.77 × 10^1^       1.73 × 10^3^       34.6
  Lungs                       2.54 × 10^−3^   9.40               2.82 × 10^2^       5.6
  Muscle                      3.03 × 10^−3^   1.12 × 10^1^       3.36 × 10^2^       6.7
  Ovaries                     3.90 × 10^−3^   1.44 × 10^1^       4.33 × 10^2^       14.4
  Pancreas                    4.53 × 10^−3^   1.68 × 10^1^       5.03 × 10^2^       10.1
  Red marrow                  2.72 × 10^−3^   1.01 × 10^1^       3.02 × 10^2^       10.1
  Osteogenic Cells            4.39 × 10^−3^   1.62 × 10^1^       4.87 × 10^2^       9.7
  Skin                        2.38 × 10^−3^   8.81               2.64 × 10^2^       5.3
  Spleen                      3.90 × 10^−3^   1.44 × 10^1^       4.33 × 10^2^       8.7
  Testes                                                                            
  Thymus                      3.09 × 10^−3^   9.92               2.97 × 10^2^       5.9
  Thyroid                     2.68 × 10^−3^   6.77 × 10^1^       2.03 × 10^3^       40.6
  Urinary Bladder Wall        1.83 × 10^−2^   1.53 × 10^1^       4.60 × 10^2^       9.2
  Uterus                      4.14 × 10^−3^   0.00 × 10          0.00               0.0
  Total Body                  3.53 × 10^−3^   1.31 × 10^1^       3.92 × 10^2^       
                              **mSv/MBq**     **mrem/mCi**       **mrem/ID**        
  Effective dose equivalent   8.35 × 10^−3^   3.09 × 10^1^       9.27 × 10^2^       
  Effective dose              4.83 × 10^−3^   1.79 × 10^1^       5.36 × 10^2^       17.9
